Patents Issued in October 18, 2016
-
Patent number: 9468648Abstract: Naturally occurring lecithins and/or oleic acid stimulate the growth and lactic acid producing activity of Lactobacillus and Bifidobacterium species of probiotic bacteria, and replace polysorbate 80 for those products. They can be used in naturally occurring form, or where they are to be combined with probiotics in a carrier, or they can be treated to yield a stable powdered form of these naturally oily compounds. They can be sold as combined prebiotic/probiotic formulations in the same carrier, or sold as separate dietary supplements, e.g., in capsule or tablet form, to be used with the probiotic formulation as desired.Type: GrantFiled: May 30, 2013Date of Patent: October 18, 2016Assignee: MASTER SUPPLEMENTS, INC.Inventors: Sonja Lea Yonak, Randolph S. Porubcan
-
Patent number: 9468649Abstract: The present invention provides methods of treating epilepsy and other neurological disorders. The methods generally involve administering to an individual in need thereof an effective amount of an agent that blocks a transforming growth factor-beta pathway.Type: GrantFiled: December 4, 2009Date of Patent: October 18, 2016Assignee: The Regents of the University of CaliforniaInventors: Daniela Kaufer, Alon Friedman, Luisa Cacheaux
-
Patent number: 9468650Abstract: The present invention relates, in general, to pattern-recognition receptors (PRRs), including toll-like receptors (TLRs), and, in particular, to a method of inhibiting nucleic acid-induced activation of, for example, endosomal TLRs using an agent that binds to the nucleic acid (“nucleic acid binding agent”), preferably, in a manner that is independent of the nucleotide sequence, the chemistry (e.g., DNA or RNA, with or without base or sugar modifications) and/or the structure (e.g., double-stranded or single-stranded, complexed or uncomplexed with, for example protein) of the nucleic acid(s) responsible for inducing TLR activation. The invention also relates to methods of identifying nucleic acid binding agents suitable for use in such methods.Type: GrantFiled: September 16, 2010Date of Patent: October 18, 2016Assignee: DUKE UNIVERSITYInventors: Bruce A. Sullenger, Jaewoo Lee
-
Patent number: 9468651Abstract: A method for removing moles includes applying a composition containing potassium hydroxide, Beijing Er Guo Tou and talcum powder on the surface of moles on human skin. The composition is applicable to benign moles and not to cancerous moles.Type: GrantFiled: December 30, 2009Date of Patent: October 18, 2016Inventor: Yuk Ming To
-
Patent number: 9468652Abstract: Some embodiments of the present disclosure include a dental gel formulation for protecting a user's teeth and gums from acid resulting from acid reflux disease or bacterial plaque. The dental gel may include a gel carrier and a treatment ingredient, the treatment ingredient being a member selected from the group consisting of an antibacterial ingredient, an acid neutralizing ingredient, a vitamin, a mineral ingredient, a probiotic, natural extracts and oils, and medication. In some embodiments, the gel carrier may be a poloxamer 407 gel, and the treatment ingredients may include sodium bicarbonate, calcium carbonate, xylitol, and optionally melatonin.Type: GrantFiled: July 15, 2014Date of Patent: October 18, 2016Inventor: Michael Yar Zuk
-
Patent number: 9468653Abstract: The present invention relates to the a bismuth-based composition, particularly involving the use of bismuth ions, particularly the Bi+3 ion, for prevention and/or treatment of the haemolytic uremic syndrome, with the invention also relating to the use of a bismuth ion in the manufacture of a medicament for the prevention and/or treatment of an infection caused by a Shiga-toxin producing Escherichia coli strain, as well as to a method for preventing and/or treating the haemolytic uremic syndrome comprising administering bismuth ions to a patient in need thereof, and a method for inhibiting dissemination of the gene encoding virulence factors of a Shiga-toxin producing Escherichia coli strain in animals and humans.Type: GrantFiled: October 10, 2011Date of Patent: October 18, 2016Assignee: Soubeiran ChobetInventor: Hector Manuel Fernandez
-
Patent number: 9468654Abstract: A drug delivery composition is disclosed which includes a triple salt proxy functional group and at least one amino acid functional group. A method of forming the drug delivery composition includes reacting a triple salt with at least one amino acid in an aqueous environment. A biodegradable fabric is disclosed which includes a polymerized structure of a triple salt proxy functional group and at least one amino acid functional group.Type: GrantFiled: April 1, 2015Date of Patent: October 18, 2016Inventor: Ali Razavi
-
Patent number: 9468655Abstract: Compositions and methods are disclosed herein for producing one or more immunoglobulins in an isolated B lymphocyte cell line. An isolated recombinant cell line includes an isolated B lymphocyte cell line capable of expressing at least one endogenous membrane immunoglobulin reactive to a first antigen and at least one exogenously incorporated nucleic acid encoding at least one secreted immunoglobulin reactive to a second antigen.Type: GrantFiled: February 17, 2015Date of Patent: October 18, 2016Assignee: Elwha LLCInventors: Roderick A. Hyde, Wayne R. Kindsvogel
-
Patent number: 9468656Abstract: The present invention relates to a method of preparing cells and in particular to a method of preparing breastmilk stem cells (BSCs) by isolation from breastmilk and subsequent culture. The invention further relates to BSCs prepared by the methods of the invention and to methods and uses thereof. In one aspect, the invention has been developed as a method for preparing and culturing BSC.Type: GrantFiled: August 12, 2014Date of Patent: October 18, 2016Assignee: Medela Holding AGInventor: Foteini Kakulas
-
Patent number: 9468657Abstract: This invention provides an effective means or method for improving lipid metabolism, and a means or method for treatment or prevention of diseases or disorders associated with the lipid metabolism disorder. Specifically, this invention relates to an agent for improving the lipid metabolism comprising, as active ingredients, broken cells of a lactic acid bacterium, and to a method for enhancing an effect of a lactic acid bacterium for improving the lipid metabolism comprising a step of breaking the lactic acid bacterium.Type: GrantFiled: June 8, 2011Date of Patent: October 18, 2016Assignee: Asahi Group Holdings, Ltd.Inventors: Futoshi Nakamura, Yu Ishida, Shigeru Fujiwara
-
Patent number: 9468658Abstract: The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.Type: GrantFiled: July 7, 2015Date of Patent: October 18, 2016Assignee: Crestovo LLCInventor: Thomas Julius Borody
-
Patent number: 9468659Abstract: Compositions and uses thereof include an admixture of a probiotic and natural phytochemicals that can affect an individual's stem cells and the inflammatory process to reduce underlying symptoms of various health issues, including arthritis, aging, and physical or athletic injuries, thereby facilitating healing and repair of tissues.Type: GrantFiled: November 6, 2014Date of Patent: October 18, 2016Assignee: NWO STEM CURE, LLCInventors: Bruce E. Heck, Dong Hyun Kim
-
Patent number: 9468660Abstract: There are provided methods and compositions useful in cell-cell fusion using Fusion Family (FF) proteins of nematode origin. There are further provided antinematodal methods and compositions, utilizing fusogenic proteins of the nematode Fusion Family.Type: GrantFiled: January 31, 2012Date of Patent: October 18, 2016Assignees: Technion Research and Development Foundation Ltd., University of Virginia Patent FoundationInventors: Benjamin Podbilewicz, Ori Avinoam, Judith M. White
-
Patent number: 9468661Abstract: The present invention provides a compound of formula (I) a method for manufacturing the compounds of the invention, and its therapeutic uses as complement pathway modulators for the treatment of ocular diseases. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.Type: GrantFiled: June 27, 2013Date of Patent: October 18, 2016Assignee: Novartis AGInventors: Eva Altmann, Ulrich Hommel, Edwige Liliane Jeanne Lorthiois, Jeurgen Klaus Maibaum, Nils Ostermann, Jean Quancard, Stefan Andreas Randl, Olivier Rogel, Anna Vulpetti
-
Patent number: 9468662Abstract: A PAT nonapeptide of formula EAKSQGGSD (SEQ ID NO: 1) can be used to treat or prevent neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease and amyotrophic lateral sclerosis. Pharmaceutical compositions containing the PAT nonapeptide can be formulated for administration by parenteral route, including the subcutaneous, intraperitoneal, intravenous or intranasal routes.Type: GrantFiled: November 2, 2015Date of Patent: October 18, 2016Assignee: ORPHITInventors: Claude Laruelle, Jamal Temsamani, Frederic Mourlane
-
Patent number: 9468663Abstract: There is disclosed herein a composition for treating gastrointestinal or neurological disorders, constipation, functional constipation, irritable bowel syndrome, diverticulitis, travelers diarrhoea, chronic idiopathic nausea, IBD-associated constipation and diarrhoea, pseudo-obstruction, diabetic gastroparesis, cyclic vomiting, reflux oesophagitis, autism enteropathy, flatulence, halitosis, chronic fatigue, bloating, proctalgia fugax, Parkinsons disease, MS, Alzheimers Disease, Motor Neurone Disease or autism, the composition comprising: (i) at least two anti-clostridial agents selected from the group consisting of: vancomycin, vancomycin derivatives, a multi-valent polymer of vancomycin, aminoglycosides, nitroimidazoles, ansamysins, nifuroxazide, colchicine, prucalopride, prokinetic agent and 5-aminosalicylic acid; or (ii) at least one anti-clostridial agent selected from the above combined with an opioid blocking agent.Type: GrantFiled: July 23, 2015Date of Patent: October 18, 2016Inventor: Thomas Julius Borody
-
Patent number: 9468664Abstract: Provided herein are liquid concentrate formulations of romidepsin. Also provided are methods for producing these formulations and uses thereof. In one embodiment, the formulation comprises romidepsin, polyethylene glycol, etanol and a citrate buffer. In another embodiment, the formulation comprises romidepsin, polyethylene glycol, etanol and an acetate buffer.Type: GrantFiled: November 17, 2015Date of Patent: October 18, 2016Assignee: Celgene CorporationInventors: Lianfeng Huang, Ho-Wah Hui, Vijay Naringrekar, Gang Yang
-
Patent number: 9468665Abstract: Nerve Growth Factor (NGF), in the form of a preparation to be administered over ocular surface, is suggested as being suitable for therapy and/or prophylaxis of intraocular tissue pathologies, with particular reference to sclera, ciliary body, crystalline lens, retina, optic nerve, vitreous body and choroidea affections. When administered in the form of external ophthalmic preparation, for example as collyrium or ointment, NGF is capable to go through ocular tissues and it has been found out that it shows a therapeutic activity not only against retina and optic nerve pathologies but also against affections involving the above reported internal structures of the eye.Type: GrantFiled: January 21, 2000Date of Patent: October 18, 2016Assignee: Dompé Farmaceutici S.p.A.Inventor: Alessandro Lambiase
-
Patent number: 9468666Abstract: Endoglin has now been shown to be an important target of therapy to reduce disease symptoms associated with heart failure, particularly cardiac fibrosis. Soluble Endoglin is identified as an anatogonist to TGF?1 activity, while membrane-bound Endoglin is identified as a necessary component to promote TGF?1 activity in heart failure. The present invention therefore features methods and kits for treatment of subject having heart failure or a related disorder by administering a composition that decreases TGF?1 signaling through either direct inhibition of membrane-bound Endoglin or promoting expression of soluble Endoglin.Type: GrantFiled: July 31, 2012Date of Patent: October 18, 2016Assignee: Tufts Medical Center, Inc.Inventors: Navin K. Kapur, Richard H. Karas
-
Patent number: 9468667Abstract: Embodiments of the present invention provide Dermal Micro-organs (DMOs), methods and apparatuses for producing the same. Some embodiments of the invention provide a DMO including a plurality of dermal components, which substantially retain the micro-architecture and three dimensional structure of the dermal tissue from which they are derived, having dimensions selected so as to allow passive diffusion of adequate nutrients and gases to cells of the DMO and diffusion of cellular waste out of the cells. Some embodiments of the invention provide methods and apparatuses for harvesting the DMO. An apparatus for harvesting the DMO may include, according to some exemplary embodiments, a support configuration to support a skin-related tissue structure from which the DMO is to be harvested, and a cutting tool able to separate the DMO from the skin-related tissue structure.Type: GrantFiled: June 30, 2013Date of Patent: October 18, 2016Assignee: Medgenics Medical Israel Ltd.Inventors: Stephen F. Bellomo, Itzhak Lippin, Guillermo Alberto Piva, Lior Rosenberg, Mordechay Bukhman, Baruch S. Stern, David Shalhevet, Menachem D. Shavitt, Andrew L. Pearlman, Noam Shani, Einat Almon
-
Patent number: 9468668Abstract: Flavored chewable wafers containing nutritional supplement formulations suitable for enhancement of cell and mitochondrial function as well as providing antioxidants and aiding in weight loss and other desirable nutritional benefits comprises enriched formulations of phospholipids, specifically identified concentrations of phosphatidylglycerol, phosphatidic acid, phosphatidylethanolamine, phosphatidylcholine, glycolipids and phosphatidylserine along with inulin and other desirable active ingredients. These edible wafer lipid combinations can be used to treat mitochondrial disorders and other nutritional deficiencies associated with medical pathologies, chronic illnesses and syndromes, or to maintain lipid balance for normal mitochondrial function, and can be administered in pleasant tasting chewable wafers.Type: GrantFiled: July 31, 2015Date of Patent: October 18, 2016Assignee: ALLERGY RESEARCH GROUP, LLCInventor: Robert Settineri
-
Patent number: 9468669Abstract: The invention provides methods and compositions for treating dysregulated blood glucose disorders.Type: GrantFiled: April 19, 2016Date of Patent: October 18, 2016Assignee: REGENTS OF THE UNIVERSITY OF MINNESOTAInventor: Amber Dianne Lockridge
-
Patent number: 9468670Abstract: Methods and composition for a melatonin signaling modulator-based diagnosis and therapy are described. For example, in certain aspects methods for administering an anti-tumor therapy using a melatonin signaling modulator are described. Furthermore, the invention provides compositions and methods for detecting biliary tract disease such as cholangiocarcinoma.Type: GrantFiled: April 2, 2012Date of Patent: October 18, 2016Assignees: Texas A&M University System, The United States of America as Represented by the Department of Veterans Affairs, Scott & White HealthcareInventors: Gianfranco Alpini, Sharon DeMorrow, Shannon Glaser
-
Patent number: 9468671Abstract: Neural outgrowth in the central nervous system is achieved by administering chondroitinase AC and/or chondroitinase B to degrade chondroitin sulfate proteoglycans that inhibit or contribute to the inhibition of nervous tissue regeneration.Type: GrantFiled: June 27, 2014Date of Patent: October 18, 2016Assignee: Acorda Therapeutics, Inc.Inventors: Elliott A. Gruskin, Jennifer F. Iaci, Andrea M. Vecchione, Sarah J. Kasperbauer, Gargi Roy
-
Patent number: 9468672Abstract: The present disclosure provides (a) isolated immunogenic PAA polypeptides; (b) isolated nucleic acid molecules encoding immunogenic PAA polypeptides; (c) vaccine compositions comprising an immunogenic PAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic PAA polypeptide; (d) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions; and (e) vaccine-based immunotherapy regimens which involve co-administration of a vaccine in combination with an immune-suppressive-cell inhibitor and an immune-effector-cell enhancer.Type: GrantFiled: March 13, 2015Date of Patent: October 18, 2016Assignee: Pfizer Inc.Inventors: Joseph John Binder, Helen Kim Cho, Michael Robert Dermyer, Karin Ute Jooss, Brian Gregory Pierce, Joyce Tsi Tan, Van To Tsai
-
Patent number: 9468673Abstract: fHBP is a protein in Neisseria meningitidis. Three families of fHBP are known. To increase the ability of a fHBP protein to elicit antibodies that are cross-reactive between the families, fHBP is selected or engineered to have a sequence which can elicit broad-spectrum bactericidal anti-meningococcal antibodies after administration to a host animal.Type: GrantFiled: January 8, 2013Date of Patent: October 18, 2016Assignee: GlaxoSmithKline Biologicals SAInventors: Mariagrazia Pizza, Maria Scarselli, Marzia Monica Giuliani, Maria Arico, Rino Rappuoli
-
Patent number: 9468674Abstract: Described herein are methods of preventing and/or treating inflammation in a barrier surface structure in an individual in need thereof by orally administering to the individual an anti-inflammatory amount of secretory IgA.Type: GrantFiled: September 24, 2013Date of Patent: October 18, 2016Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATIONInventors: Mark E. Cook, Jordan Marshall Sand, Lisa Ann Krugner-Higby, James Mukasa Ntambi
-
Patent number: 9468675Abstract: The present invention provides novel methods for reducing the serine protease and/or serine protease zymogen content of a plasma-derived protein composition. Also provided are methods for manufacturing plasma-derived protein compositions having reduced serine protease and\or serine protease zymogen content. Among yet other aspects, the present invention provides aqueous and lyophilized compositions of plasma-derived proteins having reduced serine protease and/or serine protease zymogen content. Yet other aspects include methods for treating, managing, and/or preventing a disease comprising the administration of a plasma-derived protein composition having a reduced serine protease or serine protease zymogen content.Type: GrantFiled: June 4, 2014Date of Patent: October 18, 2016Assignees: Baxalta Incorporated, Baxalta GmbHInventors: Wolfgang Teschner, Hans-Peter Schwarz, Ruth Madlener, Sonja Svatos, Azra Pljevljakovic, Alfred Weber
-
Patent number: 9468676Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat thrombosis or hypercoagulation in patients having, or at risk of developing, diseases associated with abnormal blood coagulation or fibrinolysis and/or patients which are at increased risk or are being treated by a regimen that renders the patient at increased susceptibility to hypercoagulation or thrombosis such as patients who have previously had a stroke or heart attack or persons on a treatment regimen with a drug or chemotherapy and/or radiation that is associated with increased risk of thrombosis or hypercoagulation. In preferred embodiments these patients will comprise those exhibiting elevated D-dimer or other coagulation cascade related proteins and optionally will further exhibit elevated C reactive protein prior to treatment.Type: GrantFiled: November 24, 2010Date of Patent: October 18, 2016Assignee: ALDERBIO HOLDINGS LLCInventor: Jeffrey T. L. Smith
-
Patent number: 9468677Abstract: Compositions comprising TL1A-Ig fusion proteins and methods of their use, e.g., for the treatment of diseases and disorders associated with antigen-specific immune responses, are described. Also described are combination therapies that include the administration of a TNFRSF25 agonist and an interleukin (e.g., IL-2) and/or an mTOR inhibitor (e.g., rapamycin).Type: GrantFiled: February 20, 2014Date of Patent: October 18, 2016Assignee: University of MiamiInventors: Eckhard R. Podack, Taylor H. Schreiber, Samia Q. Khan
-
Patent number: 9468678Abstract: The present disclosure provides isolated binding molecules that bind to human 4-1BB, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.Type: GrantFiled: May 13, 2014Date of Patent: October 18, 2016Assignee: Pfizer Inc.Inventors: Bianca Ahrens, Sangita M. Baxi, Timothy Scott Fisher, Richard Michael Jerome, Kathrin Ladetzki-Baehs, Theodore Oliphant, Leslie Lynne Sharp, Michael Tesar, Libbey Anne Yates, Moritz Zulley
-
Patent number: 9468679Abstract: Methods for preparing solid formulations of immunoglobulin single variable domains are provided. The methods are based on contacting solid carrier(s) with a liquid comprising the immunoglobulin single variable domains, e.g. by spraying the liquid onto the solid carrier(s), to cause granulation or coating of the carrier(s). During contacting the carrier is agitated, e.g. in a fluid bed, and the mixture of carrier and liquid is exposed to heat, e.g. a heated air stream, to evaporate the liquid.Type: GrantFiled: March 28, 2012Date of Patent: October 18, 2016Assignee: Ablynx N.V.Inventors: Ann Debunne, Veronique De Brabandere
-
Patent number: 9468680Abstract: Drugs are screened for affects on inhibiting efflux pumps and blocking gap junction communication in tumors by culturing cells to thereby form self-assembled spheroids and incubating the spheroids. Uptake of a substrate of the efflux pump and distribution of a substrate for the efflux pump within the spheroids is imaged to thereby select drugs that inhibit the efflux pump or do not block gap junction communication. Selected drugs can then be employed to treat a tumor.Type: GrantFiled: September 20, 2012Date of Patent: October 18, 2016Assignee: Brown UniversityInventors: Jeffrey R. Morgan, Toni-Marie Achilli, Anubhav Tripathi, Stephanie McCalla
-
Patent number: 9468681Abstract: Described herein are carrier nanoparticles comprising a polymer containing a polyol coupled to a polymer containing a boronic acid, configured to present the polymer containing a boronic acid to an environment external to the nanoparticle. Targeted versions of the described nanoparticles are also described, as are related compositions, methods and systems.Type: GrantFiled: March 1, 2013Date of Patent: October 18, 2016Assignee: California Institute of TechnologyInventors: Mark E. Davis, Han Han
-
Patent number: 9468682Abstract: According to this invention, compositions and methods for increasing the extent of penetration of a biologically active substance into the tissues and organs are proposed, the methods comprising administration of the biologically active substance in combination with one or more chaotropic agents, e.g., ammonium sulfate.Type: GrantFiled: April 5, 2013Date of Patent: October 18, 2016Assignee: Joint-stock company “High Tech”Inventor: Olga Klimova
-
Patent number: 9468683Abstract: The present invention relates to compositions and pharmaceutical compositions having a hyaluronic acid; a chitosan; and at least one ionic compound in hydrogel form, their use in medical applications and methods of making same as well as medical devices comprising same.Type: GrantFiled: August 21, 2013Date of Patent: October 18, 2016Assignee: UNIVERSITY OF GENEVAInventors: Olivier Jordan, Sema Gwendolyn Kaderli, Robert Gurny
-
Patent number: 9468684Abstract: The present disclosure relates to a hydrogel composition and methods of using the same. The hydrogel composition may include precursors that react with each other upon contact as well as precursors that react upon contact with an initiator. In embodiments, the resulting hydrogels may have varying levels of crosslinking with both denser and less dense regions.Type: GrantFiled: February 5, 2015Date of Patent: October 18, 2016Assignee: Covidien LPInventors: Steven Bennett, Nathaniel Mast, Kevin Lavigne, Walter Skalla
-
Patent number: 9468685Abstract: Provided are pharmaceutical liquid formulations of G-CSF, which are stable over a long time period and substantially free of excipients, as well as ready-to-use syringes containing such formulations and corresponding kits.Type: GrantFiled: January 9, 2015Date of Patent: October 18, 2016Assignee: RATIOPHARM GMBHInventors: Walter Hinderer, Heinz Lubenau
-
Patent number: 9468686Abstract: A solution in water comprising the following components at the following concentrations: (a) N×(70 to 130) g/L polyethylene glycol (PEG) having an average molecular weight of 2500 to 4500; (b) N×(1.6 to 4.0) g/L sodium chloride; (c) N×(0.2 to 0.6) g/L potassium chloride; (d) N×(0.6 to 2.2) g/L sodium bicarbonate; (e) N×an amount of preservative; (f) optionally N x an amount of flavouring; and (g) optionally N×an amount of sweetener, where N is in the range of 2 to 8. The solution is a concentrate for dilution. In use it is diluted N-fold with water to provide a solution for administration to a subject for the treatment of constipation or faecal impaction. Also provided are solutions, kits, unit doses and methods that comprise or use the solutions.Type: GrantFiled: January 28, 2014Date of Patent: October 18, 2016Assignee: NORGINE BVInventors: Chris Seldon, Dawn Padfield, Frances Morrissey
-
Patent number: 9468687Abstract: Pharmaceutical compositions comprising a nucleic acid, a gene delivery polymer, and at least one adjunctive chemotherapeutic drug for the treatment of mammalian cancer or hyperproliferative disorders and methods of using thereof for the treatment of mammalian cancer or hyperproliferative disorders by intratumoral, intraperitoneal or systemic injection.Type: GrantFiled: January 6, 2014Date of Patent: October 18, 2016Assignee: CLSN LABORATORIES, INC.Inventors: Jason G. Fewell, Majed Matar, Jennifer Rice, Danny H. Lewis, Khursheed Anwer
-
Patent number: 9468688Abstract: The present invention provides a novel boron carrier compound that can be used for boron neutron capture therapy for cancer, and that can realize improvement in the efficiency of a Drug Delivery System (DDS) and an increase in the boron concentration in a tumor. The present invention provides a boron cluster-modified PEG lipid derivative represented by Formula (I): wherein, m and n are each independently an integer of 1-4, q is an integer of 1-280, and R1 and R2 are each independently a hydrocarbon group with a carbon number of 8-22, and a molecular assembly containing the same.Type: GrantFiled: August 22, 2013Date of Patent: October 18, 2016Assignee: UNIVERSITY OF TSUKUBAInventors: Akira Matsumura, Kei Nakai, Makoto Shirakawa
-
Patent number: 9468689Abstract: Disclosed are methods, compositions and uses of high concentration antibody or immunoglobulin formulations for subcutaneous, intramuscular, transdermal or other local (regional) administration, in a volume of than 3, less than 2 or less than 1 ml. Preferably, the formulation contains a high concentration formulation (HCF) buffer comprising phosphate, citrate, polysorbate 80 and mannitol at a pH of about 5.2. The formulation more preferably comprises at least 100, 150, 200, 250 mg/ml or 300 mg/ml of antibody. The methods for preparing the high concentration formulation include ultrafiltration and diafiltration to concentrate the antibody and exchange the medium for HCF buffer. Other embodiments concern use of non-G1m1 (nG1m1) allotype antibodies, such as G1m3 and/or a nG1m1,2 antibodies. The nG1m1 antibodies show decreased immunogenicity compared to G1m1 antibodies.Type: GrantFiled: December 18, 2013Date of Patent: October 18, 2016Assignee: Immunomedics, Inc.Inventors: Li Zeng, Rohini Mitra, Edmund A. Rossi, Hans J. Hansen, David M. Goldenberg
-
Patent number: 9468690Abstract: A novel gene delivery system and recombinant adenovirus includes a decorin-encoding sequence to enhance transduction efficiency of transgenes. A pharmaceutical anti-tumor composition includes the recombinant adenovirus, as well as a pharmaceutical composition having improved tissue penetration potency and a pharmaceutical composition for treating a disease or disorder associated with accumulation of excess extracellular matrix.Type: GrantFiled: February 24, 2006Date of Patent: October 18, 2016Assignee: GENEMEDICINE CO., LTD.Inventors: Chae-Ok Yun, Joo-Hang Kim
-
Patent number: 9468691Abstract: The present invention discloses biocompatible, stable curcumin or its derivatives coated ultra-small super paramagnetic iron oxide nanoparticles (USPION) for biomedical applications. Disclosed herein is also a simple one-pot process for the synthesis of biocompatible, stable curcumin or its derivatives coated ultra-small superparamagnetic iron oxide nanoparticles in absence of a linker or binder. The curcumin or its derivatives coated ultra-small super paramagnetic iron oxide nanoparticles of the present invention retains the medicinal, radical scavenging and fluorescence properties of curcumin.Type: GrantFiled: January 17, 2013Date of Patent: October 18, 2016Assignee: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCHInventors: Alias Joy Pattayil, Kunnoth Naduvilidam Jayaprabha
-
Patent number: 9468692Abstract: Imaging agents are described that comprise labeled substrates capable of being introduced into cells via the cystine/glutamate antiporter. The substrates may be used for imaging or detecting oxidative stress in cells by introducing the labeled agents into cells via the cystine/glutamate antiporter and subsequent detection.Type: GrantFiled: January 23, 2014Date of Patent: October 18, 2016Assignee: General Electric CompanyInventors: Bruce Allan Hay, Jack Mathew Webster
-
Patent number: 9468693Abstract: Imaging agents are described that comprise labeled substrates capable of being introduced into cells via the cystine/glutamate antiporter. The substrates may be used for imaging or detecting oxidative stress in cells by introducing the labeled agents into cells via the cystine/glutamate antiporter and subsequent detection.Type: GrantFiled: January 23, 2014Date of Patent: October 18, 2016Assignee: General Electric CompanyInventors: Bruce Allan Hay, Jack Mathew Webster
-
Patent number: 9468694Abstract: The invention relates to a process for preparation of a compound of formula (I): R1 is selected from C1-6alkyl, C2-6alkenyl, and C2-6alkynyl; which comprises: (i) reaction with fluoride, suitably [18F]fluoride, of a corresponding compound of formula (II): wherein R2 is selected from hydrogen, C1-10alkyl, C1-10haloalkyl, C6-14aryl, C6-14arylalkyl, —(CH2CH2O)q—CH3 wherein q is an integer of from 1 to 10; R1 is as defined for the compound of formula (I); and R3 is a leaving group. Certain novel precursors of formula (II) and radiopharmaceutical kits containing such precursors are also claimed.Type: GrantFiled: July 27, 2015Date of Patent: October 18, 2016Assignee: GE Healthcare LimitedInventors: Anthony Eamon Storey, Clare Louise Jones, Denis Raymond Christophe Bouvet, Nicolas Lasbistes, Steven Michael Fairway, Lorenzo Williams, Alexander Mark Gibson, Robert James Nairne, Farhad Karimi, Bengt Langstrom
-
Patent number: 9468695Abstract: A UV device includes a housing having a portion configured to be removably attached to a smart device, a UV light source disposed within the housing, wherein the UV light source is configured to provide output of UV light in response to an operating powered, a communication mechanism disposed within the housing, wherein the communication mechanism is configured to receive instructions from the smart device, a control mechanism disposed within the housing, wherein the control mechanism is coupled to the UV light source, and to the communication mechanism, wherein the control mechanism is configured to provide the operating power to the UV light source, in response to the instructions received from the smart device.Type: GrantFiled: March 11, 2015Date of Patent: October 18, 2016Assignee: RAYVIO CORPORATIONInventors: Yitao Liao, Robert C. Walker
-
Patent number: 9468696Abstract: A sink insert for cleaning medical or surgical devices having lumens includes a basin and at least two pumps. The basin is shaped to be inserted into a sink and to hold cleaning liquid, and includes an additive reservoir integrally formed in its floor, having additive fill lines defining a plurality of pre-calibrated volume measurement areas for measurement of additives. Basin fill lines positioned on one or more side walls of the basin define a plurality of pre-calibrated volume measurement areas for measurement of a liquid filled into the basin to form the cleaning liquid. At least one of the two pumps has an inlet tube for drawing the cleaning liquid from the basin into the pump, and an outlet tube for pressurized output of the cleaning liquid directed to the medical or surgical device. One or more of the pumps is removable from the sink insert.Type: GrantFiled: December 17, 2014Date of Patent: October 18, 2016Assignee: PURE PROCESSING LLCInventor: Daniel Leonard Gusanders
-
Patent number: 9468697Abstract: A method of delivering a volatile material to the atmosphere in a continuous manner is disclosed. The method includes providing a delivery engine having a reservoir that includes a volatile material mixture. The volatile material mixture includes about 40% to about 100%, by total weight, of the volatile materials each having a vapor pressure at 25° C. of less than about 0.1 torr. The delivery system also includes a microporous membrane enclosing the reservoir, wherein the microporous membrane comprises an average pore size of about 0.01 to about 0.03 microns.Type: GrantFiled: January 25, 2016Date of Patent: October 18, 2016Assignee: The Procter & Gamble CompanyInventors: Dana Paul Gruenbacher, Jason John Olchovy, Scott Kendyl Stanley, James Douglas Still, Rhonda Jean Jackson, Zaiyou Liu, Walter Sordo, Stefano Deflorian, Cedric Morhain